Carlsmed, Inc. (CARL)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$15.60+0.52%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Carlsmed grows revenue to about $74.5 million in 2026. Sales rose from $13.1 million in 2025-Q3 to $16.1 million in 2026-Q1. The company is improving revenue guidance and showing growth. This could lead to a stronger business if losses shrink.
Carlsmed still loses money with operating income at -$9.3 million in 2026-Q1. Cash from operations is negative and worsening. The company may struggle to become profitable soon.
The price is about 2% below our fair value near $13. Analysts expect 52% revenue growth. We agree revenue growth is strong but losses remain.
Breaks if: cash flow worsens beyond -$13 million
Improve cash flow from operating activities to support financial stability and growth investments.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround situation, as CARL aims to improve its financial metrics over the next few years. The current thesis state indicates a cautious outlook due to recent weak performance, despite some positive earnings surprises.
The market appears to have priced in a justified valuation, with a low expectations gap. CARL trades at a premium compared to its peers, which suggests that investors may be expecting some recovery or improvement in fundamentals.
Management is focused on increasing revenue guidance, which has shown strong growth recently. However, operating losses have widened, and cash flow remains negative, indicating challenges in achieving profitability and operational efficiency.
The thesis hinges on CARL's ability to maintain revenue growth while addressing operating losses and cash flow issues. Additionally, the performance of sector leaders could influence CARL's trajectory, as positive trends in the healthcare sector may provide support.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Cash from operations was negative $5.3 million in 2025-Q4 and worsened to negative $13.0 million in 2026-Q1. Cash and equivalents declined from $97.1 million in 2026-Q1 to $89.3 million in 2026-Q2. Management continues to invest heavily, resulting in negative operating cash flow and a declining cash balance, indicating limited progress on improving cash from operations.
“Cash and cash equivalents were $89.3 million as of June 30, 2026”
“Cash and cash equivalents were $97.1 million as of March 31, 2026”
“Cash and cash equivalents were $85.8 million as of December 31, 2025”
Breaks if: operating loss worsens beyond -$9.3 million
Focus on reducing operating losses and improving operating income through expense management and revenue growth.
Stated as a priority in 3 of last 3 quarters. Operating loss increased from $6.5 million in 2025-Q4 to $11.0 million in 2026-Q2, while gross margin expanded from 73.4% to 76.8% over the same period. Management emphasizes progress on profitability path but operating losses have grown, indicating mixed delivery with margin improvement offset by higher expenses.
“Further progress on our path to profitability, gross margin expanded by 340 basis points”
“Operating expenses increased to support growth, loss from operations was $9.3 million”
“Operating loss was $6.5 million, reflecting investments in R&D and sales”
Breaks if: revenue falls below $72 million in FY26
Raise full-year 2026 revenue guidance reflecting strong volume growth and market demand.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $22.3 million in first half 2025 to $35.1 million in first half 2026, a 57% increase year-over-year in Q2 2026. Management raised full-year 2026 revenue guidance twice, most recently to $74–$78 million, reflecting strong volume growth and market demand. The trajectory is delivering consistent growth and upward guidance revisions.
“Full year 2026 revenue guidance raised to $74 million to $78 million”
“Full year 2026 revenue guidance raised to $72 million to $77 million”
“Revenue for 2026 is expected to be in the range of $70 to $75 million”
In summary, CARL is navigating a challenging environment with mixed signals on growth and profitability. The next few quarters will be critical in determining the sustainability of its recovery efforts. Not investment advice.